ICARUS-IBD

International study of COVID-19 Antibody Response Under Sustained immune suppression: A Global seroprevalence study of #COVID19 in #IBD
Funded by @HelmsleyTrust

[Matthew Edmans @MatthewEdmans]

Just arrived home from #DDW2022.

It was great to have the opportunity to present some of the work of @ICARUSIBD—all a massive team effort with colleagues @JudithWellens @craigpthomp, and many more.

[ICARUS-IBD @ICARUSIBD]

Published in The Lancet Gastroenterology and Hepatology - April 2022 - Determinants of uptake of a third dose of SARS-CoV-2 vaccines in patients with inflammatory bowel disease. https://t.co/SreKNczQ4h

[ICARUS-IBD @ICARUSIBD]

SARS-CoV-2 vaccination uptake by patients with inflammatory bowel disease on biological therapy
https://t.co/Jc1UtBd7Hh

[ICARUS-IBD @ICARUSIBD]

Keep an eye on our website for the latest updates on the ICARUS-IBD Study! We have recruited 3085 participants from around the globe and our goal is 5000 🤞https://t.co/JBpROi3TXh

[ICARUS-IBD @ICARUSIBD]

Proud to present the first data on serological response to mRNA COVID vaccines in IBD patients: https://t.co/USdjFP7huk

[ICARUS-IBD @ICARUSIBD]

@dziring @AshkanRA @clarityibd @Gut_BMJ @DCharabaty @guthealthmd @ibddoctor @IBDimmunology @IBD_FloMD @MujagicZlatan @ibdseb @charlie_lees @doc_ibd @bottomlineibd Yes, this is an important point. Also, the antibodies tested in the CLARITY study were to nucleocapsid, whereas the mRNA vaccines given in the Mount Sinai study target spike protein.

[ICARUS-IBD @ICARUSIBD]

Proud of our team's hard work to present the first data to-date on COVID vaccines in IBD patients.
Serological response to COVID-19 vaccination in IBD patients receiving biologics https://t.co/Nl7agW8M6D

[ICARUS-IBD @ICARUSIBD]

Here's the link!
https://t.co/IrsoswZwqd

[ICARUS-IBD @ICARUSIBD]

First SARS-CoV-2 seroprevalance data for IBD patients from our Mount Sinai team in NYC on medRxiv!

[ICARUS-IBD @ICARUSIBD]

@NancyLapid https://t.co/IrsoswZwqd

[ICARUS-IBD @ICARUSIBD]

Review highlighting need for large-scale, international trials to understand natural infection and vaccination responses in #IBD, and get better immunological insights!

@HelmsleyTrust @clarityibd @IOIBD1
@JudithWellens @JeanFredericCo1

https://t.co/DRIvq7DS1u

[ICARUS-IBD @ICARUSIBD]

A brief introduction to our study can be found here! https://t.co/yl1u49yoGs

[ICARUS-IBD @ICARUSIBD]

Thank you very much to our collaborators around the world who are working very hard on ICARUS-IBD!

[Colleen McGregor @ColleenMcGreg15]

Our #SARSCoV2 seroprevalence data published in @Gut_BMJ

Maintenance IFX & VDZ therapy in #IBD is not assoc. with increased seroprevalence. 1️⃣UK data & 1️⃣data from a paediatric IBD cohort.

More data keenly anticipated from @clarityibd & @ICARUSIBD

https://t.co/a0rYEiYU3o

[ICARUS-IBD @ICARUSIBD]

Very exciting data from IBD Mount Sinai, in New York

[IBD Mount Sinai @mountsinaiIBD]

Mount Sinai Dr. Mehandru describes viral sanctuaries in the #gastrointestinal tract of #COVID19 Patients, the work is published in the journal #Nature https://t.co/sozTQZEGtw